Research focuses on molecular messenger systems characterized in the Snyder laboratory which are substrates for actions of drugs of abuse. One involves a signaling cascade linking nitric oxide (NO), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the ubiquitin E3-ligase Siah-1 and nuclear targets. A second deals with inositol hexakisphosphate kinase-2 (IPK6K2) in cell death and neurotoxicity, while a third addresses inositol polyphosphate multikinase (IPMK) and neural function. The NO-GAPDH-Siahl pathway was discovered as a cell death signaling system acting via nuclear p53. Recent work reveals a physiologic role wherein nitrosylated GAPDH, responding to neuronal growth factors, via Siah-1, degrades the histone methylating enzyme SUV39H1 leading to histone acetylation, gene transcription and dendritic outgrowth. Cocaine, in behavioral stimulant doses, activates this pathway. We will elucidate this pathway. IP6K2, a mediator of apoptosis, acts via p53. We are assessing how it distinguishes cell arrest/cell death via influences upon DNA protein kinase to activate p53. Its role in cocaine and MPTP actions is being investigated. IPMK is an inositol phosphate kinase and a PI3-kinase. We recently discovered that it is physiologically nitrosylated and acetylated, then binds to CBP and CREB, apparently activating CREB genetic programs. Cocaine administration activates IPMK nitrosylation/acetylation. We will explore its neural functions using newly generated IPMK knockout mice. We recentiy discovered that IPMK binds the small G-protein Rheb, known to activate mTOR. We previously showed that IPMK binds and stabilizes mTOR. We will investigate whether IPMK/Rheb coordinately regulate mTOR signaling in the brain in response to abusable drugs.
Our research elucidates how the NO-GAPDH-Siah signaling cascade mediates neural messages including actions of cocaine. The work on IP6K2 and IPMK is similariy relevant, especially the novel potential role of nitrosylated/acetylated IPMK as a regulator of genetic programs impacted by cocaine.
|Hinkle, Jared T; Perepezko, Kate; Bakker, Catherine C et al. (2018) Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. Int J Geriatr Psychiatry 33:e131-e139|
|Hinkle, Jared T; Perepezko, Kate; Mills, Kelly A et al. (2018) Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism Relat Disord 55:8-14|
|Piard, Juliette; Umanah, George K Essien; Harms, Frederike L et al. (2018) A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. Brain :|
|Hinkle, Jared T; Perepezko, Kate; Rosenthal, Liana S et al. (2018) Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism Relat Disord 47:50-56|
|Berger, Nathan A; Besson, Valerie C; Boulares, A Hamid et al. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175:192-222|
|Chern, Yijuang; Chien, Ting; Fu, Xiuping et al. (2018) Trax: A versatile signaling protein plays key roles in synaptic plasticity and DNA repair. Neurobiol Learn Mem :|
|Paul, Bindu D; Snyder, Solomon H (2018) Gasotransmitter hydrogen sulfide signaling in neuronal health and disease. Biochem Pharmacol 149:101-109|
|Harraz, Maged M; Snyder, Solomon H (2017) Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb. Neurotherapeutics 14:728-733|
|Asrani, Kaushal; Sood, Akshay; Torres, Alba et al. (2017) mTORC1 loss impairs epidermal adhesion via TGF-?/Rho kinase activation. J Clin Invest 127:4001-4017|
|Dawson, Ted M; Dawson, Valina L (2017) Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. Annu Rev Pharmacol Toxicol 57:437-454|
Showing the most recent 10 out of 108 publications